Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli

Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli

Item

http://www.wikidata.org/entity/Q24653814

Q24653814

about

The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation The Molecular Mechanism of Shiga Toxin Stx2e Neutralization by a Single-domain Antibody Targeting the Cell Receptor-binding Domain Shiga toxin pathogenesis: kidney complications and renal failure.Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies.Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.Escherichia coli O157:H7-Clinical aspects and novel treatment approaches.Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.Retrograde Trafficking Inhibitor of Shiga Toxins Reduces Morbidity and Mortality of Mice Infected with Enterohemorrhagic Escherichia coli Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin Recent advances in understanding enteric pathogenic Escherichia coli.Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.Development and characterization of recombinant antibody fragments that recognize and neutralize in vitro Stx2 toxin from Shiga toxin-producing Escherichia coli.Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.Interaction between Shiga toxin and monoclonal antibodies: binding characteristics and in vitro neutralizing abilities.In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa.Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model.Targeting bacterial toxins.Combating multidrug-resistant Gram-negative bacterial infections.Shiga toxins: from structure and mechanism to applications.Impact of the nature and size of the polymeric backbone on the ability of heterobifunctional ligands to mediate shiga toxin and serum amyloid p component ternary complex formation.Isolation of B subunit-specific monoclonal antibody clones that strongly neutralize the toxicity of Shiga toxin 2.Mouse Models for Drug Discovery. Can New Tools and Technology Improve Translational Power?Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance.Shiga Toxin Therapeutics: Beyond Neutralization.Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody.Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era.

P2860

Q26748672-A68D2174-9BCF-4243-B29F-22F357A532BE Q27684790-FE970FD8-8E13-4CBA-A9C1-A102CDF50B73 Q33397541-CE8B0FBE-584D-49A2-AD03-09DAE89A3033 Q33402784-C9D35025-0F4D-47DE-82DB-DAF1D5B6C998 Q33404149-F263AFBF-2FFC-4385-A795-1A95093E78C1 Q33404448-D1EE5AB5-6EE6-44D7-BF14-3E7248406B1D Q33418526-CCE62132-D547-45A8-93EF-697F3D58256F Q33422946-9BAE8EFB-3361-4F54-811F-DDF48F77F652 Q34315661-CEA84F2E-2F24-4EA1-BBEC-59DE551185C6 Q34375210-01681AC8-5E0C-46E6-8CA3-2ABB7F04E463 Q34447679-673D0DEF-EF5F-49A8-B64B-0D6B66D8377C Q35172579-10FD7D44-DE76-46B5-8CD7-4168E69C49AF Q35221158-73E6E034-1EBB-4094-934A-6A36C2770E5B Q35581606-3AB0B0E3-3EFD-488A-B23A-C27F94456C7E Q35805321-A2F9F334-797E-4CB3-9B30-FB4F81FAD862 Q36329665-F05F9DDD-A860-439E-8EB3-0121C75AB72F Q36613653-A845A06E-9F15-4874-9CDC-3F063D51F430 Q36841541-2A98C2D5-2AC5-4B90-B6D5-BC64A3C0CA7B Q37332203-C594955F-4825-4484-91BE-2B9C210B7F6F Q37672981-521A819D-3A3B-4BDC-A33A-581E31544CAC Q37996325-A0D061FE-72BB-483F-ADE8-C6F1C47C610A Q38161570-DEE16E38-C1BF-4B2A-9CC4-777D9E78EC47 Q38674171-67527D73-39CB-4488-B861-05330012D164 Q38843829-B04714EB-1F62-452E-94F3-E64DEE34C09E Q38927469-41937FBD-A447-4695-A2A9-536E703D4CA3 Q39161687-673AD586-717A-402F-9716-F0DA6CBE67D0 Q39197564-3A2C89AA-7E27-45FB-B026-DAEF7D081C79 Q41669177-6DC7966A-14BB-4169-A394-6CC03F939E4B Q46523280-6AF9D7A0-7791-45C0-B3C0-E5EF944FE75D Q46866013-5575661D-1062-495F-A746-87F403A2ECEA Q53122163-1DBF84BE-89FE-4462-9A1D-97E1B50C8F8F Q53718587-2536312D-9191-4603-877A-D1DFE0F0C08C

P2860

Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli

Item

http://www.wikidata.org/entity/Q24653814

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu